Gregg Lanier, MD
Advanced Heart Failure and Transplant Cardiology · Hawthorne, NYNPI 1720099732
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $209,370 of the $239,493 with a category attached, or 87.4%. 17 manufacturers reported payments, led by United Therapeutics Corporation at 37.4% of the total. Among advanced heart failure and transplant cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $663.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$90K
- Actelion Pharmaceuticals US, Inc.$51K
- Merck$45K
- Bayer$28K
- Pfizer$25K
- Abbott$270
- plus $762 from 11 others
Across 9 payments — averaging $1094.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$7K
- Novartis$3K
What the payments were for
- Consulting fees$9,4514%
- Speaking & faculty fees$209,37087%
- Travel & lodging$11,0285%
- Food & beverage$9,3864%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 125 | $89,564 |
| Actelion Pharmaceuticals US, Inc. | 69 | $50,792 |
| Merck | 61 | $44,694 |
| Bayer | 37 | $28,456 |
| Pfizer | 28 | $24,953 |
| Abbott | 7 | $270 |
| Akcea Therapeutics, Inc. | 4 | $172 |
| Novartis | 16 | $170 |
| Sobi, Inc | 1 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $69 |
| Abiomed | 2 | $54 |
| AstraZeneca | 2 | $41 |
| Boehringer Ingelheim | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Medtronic | 1 | $16 |
| Preventice Services, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$239,493 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 153 | $3,538,836 |
| VyndamaxTafamidis | 68 | $1,679,731 |
| OpsumitMacitentan | 130 | $1,628,398 |
| AdempasRiociguat | 111 | $1,548,792 |
| Orenitram ErTreprostinil Diolamine | 93 | $1,365,954 |
| UptraviSelexipag | 20 | $490,052 |
| WinrevairSotatercept-Csrk | 30 | $434,891 |
| Ambrisentan | 74 | $337,070 |
| VyndaqelTafamidis Meglumine | 12 | $310,951 |
| Tadalafil | 150 | $235,986 |
| EntrestoSacubitril/Valsartan | 148 | $203,223 |
| JardianceEmpagliflozin | 153 | $145,630 |
| EliquisApixaban | 130 | $142,445 |
| FarxigaDapagliflozin Propanediol | 89 | $101,369 |
| AdcircaTadalafil | 12 | $49,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $24,953 | $2,133,128210 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $50,792 | $2,118,450150 claims |
| BayerAdempas | $28,456 | $1,548,792111 claims |
| MerckWinrevair, Verquvo | $44,694 | $479,74164 claims |
| NovartisEntresto | $170 | $203,223148 claims |
| Boehringer IngelheimJardiance | $30 | $145,630153 claims |
| AstraZenecaFarxiga | $41 | $101,36989 claims |
| United Therapeutics CorporationAdcirca | $89,564 | $49,23612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Hawthorne
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.